Login to Your Account



Surprise pivotal trial news wounds Macrocure shares

By Michael Fitzhugh
Staff Writer

Thursday, August 20, 2015
Macrocure Ltd. shares (NASDAQ:MCUR) hit an all-time low on Thursday after a futility analysis of partial data from a pivotal phase III study revealed that the company's sole candidate, the cell therapy Curexcell, is unlikely to meet its primary endpoint of helping heal venous leg ulcers faster than a placebo.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription